What is the Purpose of this Study?
The purpose of this study is to determine the safety and effectiveness of an investigational immunotherapeutic drug called IMC-F106C in multiple cancers (endometrial, ovarian, melanoma, ocular melanoma, triple-negative breast, lung, and bladder cancer) expressing a specific protein. IMC-F106C has been developed to activate the body’s own immune system to fight tumors overexpressing a specific protein. Patients will be eligible for the study if they express this protein.
The study will be divided into several parts: a phase I monotherapy group looking for the appropriate dose, phase I combination therapy groups with other immunotherapies, and an expanded phase II group, once the appropriate dose is established. The dose of IMC-F106C participants receive will depend on when they join the study. The first group of patients will receive a dose of the drug, with each new group receiving a higher dose.
Eligibility
- 1. ECOG PS 0 or 1
- 2. HLA-A\*02:01 positive
- 3. PRAME positive tumor
- 4. Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies
Where can I participate?
CS Cancer at The Angeles Clinic and Research Institute : Saba Mukarram
More about this Clinical Trial
What is the full name of this clinical trial?
IMC-F106C-101: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A 02:01-Positive Participants with Advanced PRAME-Positive Cancers